Referencia número: HY-N0656A

(+)-Usnic acid

Name: (+)-Usnic acid
Brand: MedChemExpress
SKU: HY-N0656A
Price: 25.00 USD
Availability: InStock
Rating: 5 (2 reviews)

2 Cited Publications

Revisión del cliente

Based on 2 publication(s) in Google Scholar

(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of mTOR, and inhibits mTORC1/2 activity. (+)-Usnic acid inhibits the phosphorylation of mTOR downstream effectors: Akt (Ser473), 4EBP1, S6K, induces autophay, with anti-cancer and anti-inflammatory activity. (+)-Usnic acid possesses antimicrobial activity against a number of planktonic gram-positive bacteria, including Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 99.64%
No. CAS: 7562-61-0
Fòrmula: C₁₈H₁₆O₇
Peso molecular:344.32

Almacenamiento:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

(+)-Usnic acid Chemical Structure

No. CAS: 7562-61-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (2)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo (8)
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

^[1]

mTORC1

mTORC2

Ver todos los productos específicos de isoformas mTOR :

Cellular Effect

Cell Line	Type	Value	Description	References
3LL cell line	IC₅₀	35.1 μM Compound: (-)-UA, usnic acid	Cytotoxicity against mouse 3LL CRL 1642 cells after 48 hrs by MTT assay Cytotoxicity against mouse 3LL CRL 1642 cells after 48 hrs by MTT assay	[PMID: 18558490]
BT-474	IC₅₀	15.1 μM Compound: 1	Antiproliferative activity against human BT-474 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human BT-474 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
DU-145	IC₅₀	45.9 μM Compound: (-)-UA, usnic acid	Cytotoxicity against human DU145 ATCC HTB 81 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 ATCC HTB 81 cells after 72 hrs by MTT assay	[PMID: 18558490]
K562	IC₅₀	21.8 μM Compound: (-)-UA, usnic acid	Cytotoxicity against human K562 ATCC CCL 243 cells after 72 hrs by MTT assay Cytotoxicity against human K562 ATCC CCL 243 cells after 72 hrs by MTT assay	[PMID: 18558490]
L1210	IC₅₀	17.4 μM Compound: (-)-UA, usnic acid	Cytotoxicity against mouse L1210 ATCC CCL 219 cells after 48 hrs by MTT assay Cytotoxicity against mouse L1210 ATCC CCL 219 cells after 48 hrs by MTT assay	[PMID: 18558490]
MCF7	IC₅₀	11.2 μM Compound: 1	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
MCF7	IC₅₀	51.7 μM Compound: (-)-UA, usnic acid	Cytotoxicity against human MCF7 ATCC HTB 22 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 ATCC HTB 22 cells after 72 hrs by MTT assay	[PMID: 18558490]
MDA-MB-231	IC₅₀	13.1 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
MDA-MB-231	IC₅₀	13.7 μM Compound: 1	Antimigratory activity in human MDA-MB-231 cells assessed as inhibition of cell migration after 23 hrs by by scratch wound healing assay Antimigratory activity in human MDA-MB-231 cells assessed as inhibition of cell migration after 23 hrs by by scratch wound healing assay	[PMID: 28245124]
MDA-MB-231	IC₅₀	14.2 μM Compound: 1	Anti-invasive activity in human MDA-MB-231 cells after 24 hrs by microscopic analysis Anti-invasive activity in human MDA-MB-231 cells after 24 hrs by microscopic analysis	[PMID: 28245124]
MDA-MB-468	IC₅₀	13.7 μM Compound: 1	Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
MDCK	ED₅₀	13.1 μM Compound: (-)-1	Antiviral activity against rimantidine, amantidine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication after 1 hrs by hemagglutination assay Antiviral activity against rimantidine, amantidine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication after 1 hrs by hemagglutination assay	[PMID: 25464881]
MDCK	ED₅₀	14.5 μM Compound: (-)-1	Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method	[PMID: 23099095]
SK-BR-3	IC₅₀	14.4 μM Compound: 1	Antiproliferative activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
T47D	IC₅₀	15.9 μM Compound: 1	Antiproliferative activity against human T47D cells incubated for 72 hrs by MTT assay Antiproliferative activity against human T47D cells incubated for 72 hrs by MTT assay	[PMID: 28245124]
U-251	IC₅₀	19.7 μM Compound: (-)-UA, usnic acid	Cytotoxicity against human U251 RCB 0641 cells after 72 hrs by MTT assay Cytotoxicity against human U251 RCB 0641 cells after 72 hrs by MTT assay	[PMID: 18558490]

In Vitro

(+)-Usnic acid (10_-6.5-10_-3.5 M, 72 h) exhibits antiproliferative activity against breast cancer cell lines^[1].
(+)-Usnic acid ( 15 μM, 72 h) induces autophagy and inhibits cell migration and invasion in human breast cancer cell lines^[1].
(+)-Usnic acid (0.2% (wt/vol), 3 days) inhibits biofilm formation by S. aureus. with a MICs value of 32 μg/mL^[2].

mean IC₅₀±SEM of (+)-Usnic acid against each breast cancer cell line^[1]

Breast cancer cell line	MDA-MB-231	MDA-MB-468	MCF-7	T-47D	BT-474	SK-BR-3
IC₅₀ (μM)	13.1	13.7	11.2	15.9	15.1	14.4

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[1]

View Protocol

Cell Line:

Breast cancer cell lines
Concentration:

10_-6.5-10_-3.5 M
Incubation Time:

72 h
Result:

Exhibited a moderate, albeit pan antiproliferative activity against breast cancer cell lines at low micromolar concentrations.

Cell Autophagy Assay^[1]

View Protocol

Cell Line:

Breast cancer cell lines
Concentration:

15 μM
Incubation Time:

72 h
Result:

Induced distinct autophagic vacuoles and upregulated the autophagic marker LC3 and Beclin-1.

Chemical Information

No. CAS 7562-61-0
Appearance Solid
Peso molecular 344.32
Fòrmula C₁₈H₁₆O₇
Color Light yellow to yellow
SMILES

O=C([C@@]1(C)C(OC2=C(C(C)=O)C(O)=C(C)C(O)=C12)=C3)C(C(C)=O)C3=O
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (2)

All

Sort by:

Journal Impact Factor

ACS Infect Dis

Restoring Colistin Sensitivity and Combating Biofilm Formation: Synergistic Effects of Colistin and Usnic Acid against Colistin-Resistant Enterobacteriaceae. [Abstract]

2023 Dec 8;9(12):2457-2470. PMID: 37944020
Allergy Asthma Clin Immunol

KIF2A decreases IL-33 production and attenuates allergic asthmatic inflammation. [Abstract]

2022 Jun 19;18(1):55. PMID: 35718777

Solvente y solubilidad

In Vitro:

DMSO : ≥ 1.92 mg/mL (5.58 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9043 mL

14.5214 mL

29.0428 mL

5 mM

0.5809 mL

2.9043 mL

5.8085 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.63 mg/mL (1.83 mM); Clear solution

This protocol yields a clear solution of ≥ 0.63 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (6.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

All Signal Pathway Related Molecular Biology Animals and Diseases Histomorphology

Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of ³²P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (285 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Ebrahim HY, et al. Usnic Acid Benzylidene Analogues as Potent Mechanistic Target of Rapamycin Inhibitors for the Control of Breast Malignancies. J Nat Prod. 2017 Apr 28;80(4):932-952. [Content Brief]

[2]. Francolini I, et al. Usnic acid, a natural antimicrobial agent able to inhibit bacterial biofilm formation on polymer surfaces. Antimicrob Agents Chemother. 2004;48(11):4360-4365. [Content Brief]

[3]. Vijayakumar CS, et al. Anti-inflammatory activity of (+)-usnic acid. Fitoterapia. 2000 Sep;71(5):564-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9043 mL	14.5214 mL	29.0428 mL	72.6069 mL
DMSO	5 mM	0.5809 mL	2.9043 mL	5.8086 mL	14.5214 mL

Bioz

Keywords

(+)-Usnic acid

2 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

(+)-Usnic acid

Publications Citing Use of MedChemExpress (MCE) (+)-Usnic acid

Ver todos los productos específicos de isoformas mTOR